Video Experimental Relacionado
Updated: Sep 10, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
La colchicina como tratamiento complementario para la fibrilación auricular: una revisión sistemática y un
QuraTul Ain1, Tahira Irshad2, Mahnoor Usman2
1From the Department of Cardiology, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan.
Cardiology in review
|August 22, 2025
Resumen
La colchicina, un medicamento antiinflamatorio, reduce significativamente la recurrencia de la fibrilación auricular (FA) después de la ablación con catéter. Si bien aumenta los efectos secundarios gastrointestinales, ofrece una estrategia prometedora para mejorar las tasas de éxito de la ablación.
Área de la Ciencia:
- Cardiología
- Farmacología
Sus antecedentes:
- La recurrencia de la fibrilación auricular (FA) después de la ablación por catéter es un problema clínico significativo.
- La inflamación postprocedural es un factor clave que contribuye a la recurrencia de la FA.
- La colchicina, un agente antiinflamatorio, se está investigando para mitigar esta recurrencia.
Objetivo del estudio:
- Evaluar la eficacia y seguridad de la colchicina en la prevención de la recurrencia de la FA después de la ablación por catéter.
- Evaluar el impacto de la colchicina en los resultados secundarios como la pericarditis y los efectos secundarios.
Principales métodos:
- Un metanálisis de 8 estudios (N=3784) incluyendo ensayos controlados aleatorios (ECA) y estudios observacionales.
- Búsqueda de literatura en las bases de datos de PubMed, Embase, Scopus y Cochrane hasta marzo de 2025.
- Los datos se agruparon utilizando un modelo de efectos aleatorios con análisis de subgrupos y sensibilidad.
Principales resultados:
- La colchicina redujo significativamente la recurrencia de la FA (RR=0,75, P=0,04), con un efecto más fuerte en los ECA (RR=0,60, P=0, 0004).
- Se observó un aumento del riesgo de efectos secundarios gastrointestinales (RR=2,34, P=0,01).
- No hay efecto significativo en la pericarditis, hospitalizaciones o resultados compuestos.
Conclusiones:
- La colchicina demuestra eficacia en la reducción de la recurrencia de la FA después de la ablación, especialmente en ECA.
- La intolerancia gastrointestinal es una preocupación, pero la colchicina puede ser un valioso tratamiento complementario.
- Se necesitan más ensayos a gran escala para confirmar la eficacia y optimizar la dosificación.
Videos de Conceptos Relacionados
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
01:17Pericarditis III: Medical Management
26
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
987
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
987
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847